The Global Antibiotic Research and Development Partnership– GARDP and Bugworks are working together on research to determine the safety profile of a novel class of broad-spectrum antibiotic compounds focused on treating serious illnesses caused by multi drug resistant bacteria.
Bugworks is now undertaking a First-in-Human, Phase 1 trial in Adelaide, Australia, to investigate the safety profile of BWC0977, a new antibiotic molecule. It is intended for use in both acute care settings to treat patients with severe bacterial infections. CARB-X, a global non-profit alliance dedicated to expediting antibacterial medicines to combat drug-resistant bacteria, is funding the Phase 1 study. GARDP is funding cardiac safety research as part of an ongoing Phase 1 trial, which will give a thorough assessment of the compound’s cardiovascular risk. The study will give a more exact indication of the molecule’s proclivity for causing arrhythmia, which is an abnormal heartbeat, a common side effect of several antibiotics. This will aid in decision-making and the quickening of this compound’s clinical development.
They can strive to avert a global problem of antibiotic resistance through innovative collaborations like the one with Bugworks. They are also looking forward to evaluating Australia’s competence and facilities for Phase I clinical trials of new treatments, said GARDP’s Project Lead for Serious Bacterial Infections, François Franceschi.
The support for the cardiac safety study comes after GARDP and Bugworks signed a memorandum of understanding in August 2020 to support the growth and accessibility of antibiotic treatments.
Their ultimate goal is to produce a highly distinctive medicine that might be used in all regions around the world that urgently need creative treatments to combat drug-resistant viruses and bacteria, said co-founder and CEO of Bugworks Research, Anand Anandkumar. Bugworks is an antimicrobial resistance medication development firm with offices in India, Australia, and the United States. Its goal is to find new treatments for major drug-resistant bacterial diseases.
The molecule belongs to a new class of compounds that have been shown to have wide-ranging antibacterial action in preclinical studies. The chemical is being studied because of its potential to treat a variety of illnesses, notably urinary tract infections, bloodstream infections, intra-abdominal infections, and pneumonia. Furthermore, BWC0977 has the potential to be developed both as an oral and an injectable formulation.
